Virtus Investment Advisers Inc. purchased a new stake in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 13,950 shares of the company's stock, valued at approximately $196,000.
Other large investors also recently modified their holdings of the company. Mainstream Capital Management LLC bought a new position in SI-BONE during the 4th quarter worth $53,000. R Squared Ltd bought a new position in SI-BONE during the 4th quarter worth $73,000. KLP Kapitalforvaltning AS bought a new position in SI-BONE during the 4th quarter worth $97,000. Proficio Capital Partners LLC bought a new position in SI-BONE during the 4th quarter worth $155,000. Finally, ProShare Advisors LLC bought a new position in SI-BONE during the 4th quarter worth $163,000. 98.11% of the stock is currently owned by institutional investors.
Insider Activity
In other news, insider Anthony J. Recupero sold 3,311 shares of the firm's stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $14.15, for a total value of $46,850.65. Following the completion of the sale, the insider now directly owns 284,555 shares in the company, valued at $4,026,453.25. This trade represents a 1.15% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Michael A. Pisetsky sold 3,128 shares of the firm's stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total transaction of $44,229.92. Following the completion of the transaction, the senior vice president now directly owns 244,878 shares in the company, valued at approximately $3,462,574.92. The trade was a 1.26% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 92,565 shares of company stock worth $1,669,871 in the last three months. Company insiders own 4.00% of the company's stock.
Wall Street Analyst Weigh In
SIBN has been the subject of several analyst reports. Truist Financial raised their target price on SI-BONE from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 target price on shares of SI-BONE in a research report on Tuesday, May 6th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $24.00 price target on shares of SI-BONE in a report on Tuesday, May 6th.
Read Our Latest Analysis on SI-BONE
SI-BONE Trading Down 0.2%
SI-BONE stock traded down $0.04 during trading hours on Friday, reaching $18.38. 273,310 shares of the company's stock were exchanged, compared to its average volume of 374,592. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. The firm's 50 day simple moving average is $15.24 and its 200 day simple moving average is $15.20. SI-BONE, Inc. has a twelve month low of $11.70 and a twelve month high of $20.05. The firm has a market capitalization of $783.26 million, a PE ratio of -19.98 and a beta of 0.82.
SI-BONE (NASDAQ:SIBN - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.09. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The firm had revenue of $47.29 million during the quarter, compared to the consensus estimate of $45.13 million. Research analysts predict that SI-BONE, Inc. will post -0.78 earnings per share for the current year.
SI-BONE Profile
(
Free Report)
SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.
Featured Stories
Before you consider SI-BONE, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SI-BONE wasn't on the list.
While SI-BONE currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
